Atmo Biosciences Pty Ltd

Project Title: Acceleration of Atmo Gas Capsule Commercialisation to Pivotal Trial Readiness

According to the Australian Government, functional gastrointestinal disorders (FGIDs) develop in around 1 in 5 Australians. These include disorders of gastrointestinal motility, which are associated with debilitating symptoms, significant morbidity, and high healthcare costs. The diagnosis, treatment, and management of these conditions remains challenging, due to a lack of definitive diagnostic tests or biomarkers.

Atmo Biosciences (Atmo) aims to address this significant unmet clinical need by developing an ingestible medical device to aid the diagnosis of gastrointestinal motility disorders, such as gastroparesis and slow transit constipation. The Atmo Gas Capsule enables the measurement of gastrointestinal transit times. The core technology of this device involves a single-use ingestible capsule, which senses clinically valuable gaseous biomarkers as it transits through the gut. This device has been evaluated in human pilot trials, paving the way for productisation and regulatory submission of a motility and transit time (MTT) product.

Atmo's next milestone will be the completion of a pivotal clinical trial prior to regulatory submission. This BMTH project will accelerate the commercialisation of the Atmo Gas Capsule, by facilitating product testing, pivotal trial planning, and regulatory document preparation.

The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.

BMTH Round: Four

State: Victoria

Project Partners: Not applicable


  • MTPConnect Grant: $343,310
  • Industry Contribution: $676,403

Duration: May 2022 - March 2023

Visit Atmo Biosciences for more information  |  Twitter: @AtmoBio  |   LinkedIn: Atmo Biosciences

Contact: Malcolm Hebblewhite